Banco Santander (SAN) 7.28 $SAN
Banco Santander Has Returned 23.1% Since SmarTrend Recommendation (SAN)
Comtex SmarTrend(R) - Fri Mar 20, 5:00PM CDT
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 6 months, Banco Santander has returned 23.13% as of today's recent price of $7.28.
SAN: 7.28 (+0.41)
Banco Santander (SAN) Stock Rises Today as Euro Strengthens
at The Street - Fri Mar 20, 11:20AM CDT
Shares of Spanish bank Banco Santander (SAN) were up in afternoon trading Friday as the euro strengthened against the dollar.
SAN: 7.28 (+0.41)
5 Breakout Stocks to Trade for Gains After the Fed's Bombshell
at The Street - Thu Mar 19, 8:03AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
SAN: 7.28 (+0.41), UN: 43.00 (+0.69), SNY: 50.64 (+1.17), GOOG: 560.36 (+2.37), NVS: 101.68 (+1.81)
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)
PR Newswire - Thu Mar 19, 6:00AM CDT
Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
38.61% Edge For 5 Global Highest Yield, Lowest Price, March Stocks
Fredrik Arnold - at Seeking Alpha - Wed Mar 18, 5:40PM CDT
TGA: 3.35 (+0.20), SAN: 7.28 (+0.41), BAK: 7.40 (+0.22), CPL: 12.09 (+0.87), CIG: 3.92 (+0.30), EC: 15.12 (+0.70), SBS: 5.85 (+0.45), ELP: 10.76 (+0.72), VIV: 15.35 (-0.07)
What do CCAR results mean for the biggest US banks?
John Maxfield and Kristine Harjes, The Motley Fool - Motley Fool - Wed Mar 18, 1:46PM CDT
All 31 of the nation's largest banks passed the first round of stress testing by the Federal Reserve, some with flying colors and others by the skin of their teeth. Second round results, announced this week, brought a few surprises. The Fool's...
SAN: 7.28 (+0.41), GS: 193.13 (+3.16), JPM: 61.75 (+0.55), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), MS: 36.50 (+0.39)
4 Energetic Global Dividend Dogs Flash 85% To 134% March Upsides
Fredrik Arnold - at Seeking Alpha - Wed Mar 18, 8:58AM CDT
SID: 1.78 (+0.11), TGA: 3.35 (+0.20), SAN: 7.28 (+0.41), E: 34.78 (+1.59), BAK: 7.40 (+0.22), CPL: 12.09 (+0.87), CIG: 3.92 (+0.30), TOT: 50.65 (+1.87), EC: 15.12 (+0.70), SBS: 5.85 (+0.45), ELP: 10.76 (+0.72), RIO: 43.58 (+1.50), VIV: 15.35 (-0.07), STO: 17.72 (+0.62)
Nasacort® Allergy 24HR Partners with The Book of Awesome Author and Renowned Smell Expert to Celebrate the Happy Smells of Spring
PR Newswire - Wed Mar 18, 7:45AM CDT
Nasacort® Allergy 24HR is teaming up with Neil Pasricha, an allergy sufferer and bestselling author of The Book of Awesome, as well as Dr. Charles J. Wysocki, a renowned expert on the science of smell, to educate Americans about the importance of smell and encourage them to celebrate the "awesome" scents of spring that often make us happy. Nasacort Allergy 24HR is scent and alcohol free and is available over-the-counter (OTC) at full prescription strength to help relieve nasal allergy symptoms like congestion, so even the worst allergy sufferer can enjoy the Happy Smells of spring.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
See How These Stocks Chosen 3 Years Ago Are Performing Today
Jae Jun - Seeking Alpha - Tue Mar 17, 2:39PM CDT
Got a nice surprise the other day. While rummaging through my documents and investing folders, I came across a simple test I ran in 2012 and 2013. It was a basic experiment where I asked old school value readers to submit and vote for 10 stocks to be...
VRX: 204.26 (+2.17), AEY: 2.34 (+0.01), BAC: 15.84 (+0.23), GLW: 23.39 (+0.26), WDC: 100.44 (+1.14), ORCL: 44.41 (+0.25), NOV: 49.66 (+1.77), SAN: 7.28 (+0.41), DLB: 39.25 (-0.03), GS: 193.13 (+3.16), GRVY: 0.49 (unch), AIG: 55.94 (+0.29), CAT: 81.19 (+1.10), CVX: 107.03 (+2.28), MSFT: 42.88 (+0.60), AAPL: 125.90 (-1.60)
GE Sells Aussie & Kiwi Finance Units to Trim Credit Risks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 2:49PM CDT
General Electric Company (GE) recently divested its financial services units in Australia and New Zealand for an enterprise value of A$8.2 billion ($6.3 billion).
SAN: 7.28 (+0.41), GE: 25.40 (+0.07), DB: 34.15 (+1.23), SYF: 32.25 (-0.12), KKR: 23.12 (+0.31)
As Volatility Creeps Back Up Towards Normal Levels, More Buying Opportunities Emerge
Claudio Brocado - at Seeking Alpha - Mon Mar 16, 2:49AM CDT
What I continue to call the most hated equity secular bull market of my career marches on, despite lingering geopolitical worries. There are no doubt many negatives and well known headwinds. Nevertheless, the positive forces pushing this bull market...
SAN: 7.28 (+0.41), QCOM: 70.04 (+0.21)
General Electric Sells Australia Unit For $6.3 Billion
at Investor's Business Daily - Sun Mar 15, 12:01PM CDT
General Electric (GE) will sell its consumer finance unit for Australia and New Zealand to Varde, KKR (KKR) and Deutsche Bank (DB) with an enterprise value of A$8.2 billion or $6.3 billion, the acquiring companies said Sunday. The local GE Capital...
SAN: 7.28 (+0.41), GE: 25.40 (+0.07), WMT: 83.24 (+1.72), DB: 34.15 (+1.23), SYF: 32.25 (-0.12), GPS: 43.16 (+0.39), KKR: 23.12 (+0.31)
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Bank Stock Roundup: Banks Rejoice on 2015 Capital Plan Approval amid Legal Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 2:45PM CDT
Over the last five trading days, optimism rose among investors as the Federal Reserve approved most of the banks' 2015 Capital Plan after clearance of the stress tests last week. This year, 28 financial institutions out of 31 in the Comprehensive Capital Analysis and Review (CCAR) got the Fed's approval.
SAN: 7.28 (+0.41), COF: 81.13 (+0.51), JPM: 61.75 (+0.55), USB: 44.86 (+0.42), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), WFC: 56.01 (+0.50), PNC: 95.97 (+1.10)
Stock Market News for March 13, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 9:10AM CDT
Benchmarks snapped two-day losses to end in the green on Thursday as mixed economic data reduced fears about sooner-than-expected rate hike
SAN: 7.28 (+0.41), GS: 193.13 (+3.16), MPC: 102.26 (+2.20), CHK: 13.61 (+0.11), C: 52.98 (+0.60), EOG: 90.68 (+1.15), DB: 34.15 (+1.23), WFC: 56.01 (+0.50), INTC: 31.31 (+0.57), KKD: 20.41 (-0.11), CVX: 107.03 (+2.28), MS: 36.50 (+0.39)
Santander Launches The I LOVE MY BANK(SM) Initiative
PR Newswire - Thu Mar 12, 11:33AM CDT
Santander Bank, N.A., announced today the launch of its I LOVE MY BANK initiative. The innovative colleague engagement and customer service program is part of the Bank's broader 2015 effort to strengthen its connection to its customers and colleagues - its two most important constituencies - through investing resources into enhancing those relationships.
SAN: 7.28 (+0.41)
Should Bank of America’s Stress Test Results Worry Shareholders?
Matthew Frankel, The Motley Fool - Motley Fool - Thu Mar 12, 11:04AM CDT
On Wednesday, the Federal Reserve announced the results of the second round of stress tests, and 29 of the 31 banks who were tested received approval for the capital plans they submitted. However, in arguably the biggest surprise of the stress tests,...
SAN: 7.28 (+0.41), DB: 34.15 (+1.23), BAC: 15.84 (+0.23)
Fed Approves Most Capital Plans: Banks on Path to Recovery? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 10:14AM CDT
Following the release of the Dodd-Frank Act supervisory stress test 2015 (DFAST 2015) results last week, the Federal Reserve approved the capital plans of 28 financial institutions out of 31 in the Comprehensive Capital Analysis and Review (CCAR).
FITB: 19.48 (+0.26), STT: 76.24 (+1.41), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), WFC: 56.01 (+0.50), MS: 36.50 (+0.39), SAN: 7.28 (+0.41), GS: 193.13 (+3.16), JPM: 61.75 (+0.55), COF: 81.13 (+0.51), USB: 44.86 (+0.42), PNC: 95.97 (+1.10), BK: 40.57 (+0.27)
Banco Santander Has Returned 23.1% Since SmarTrend Recommendation (SAN)
Comtex SmarTrend(R) - Fri Mar 20, 5:00PM CDT
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 6 months, Banco Santander has returned 23.13% as of today's recent price of $7.28.
SAN: 7.28 (+0.41)
Banco Santander (SAN) Stock Rises Today as Euro Strengthens
at The Street - Fri Mar 20, 11:20AM CDT
Shares of Spanish bank Banco Santander (SAN) were up in afternoon trading Friday as the euro strengthened against the dollar.
SAN: 7.28 (+0.41)
5 Breakout Stocks to Trade for Gains After the Fed's Bombshell
at The Street - Thu Mar 19, 8:03AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
SAN: 7.28 (+0.41), UN: 43.00 (+0.69), SNY: 50.64 (+1.17), GOOG: 560.36 (+2.37), NVS: 101.68 (+1.81)
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)
PR Newswire - Thu Mar 19, 6:00AM CDT
Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
38.61% Edge For 5 Global Highest Yield, Lowest Price, March Stocks
Fredrik Arnold - at Seeking Alpha - Wed Mar 18, 5:40PM CDT
TGA: 3.35 (+0.20), SAN: 7.28 (+0.41), BAK: 7.40 (+0.22), CPL: 12.09 (+0.87), CIG: 3.92 (+0.30), EC: 15.12 (+0.70), SBS: 5.85 (+0.45), ELP: 10.76 (+0.72), VIV: 15.35 (-0.07)
What do CCAR results mean for the biggest US banks?
John Maxfield and Kristine Harjes, The Motley Fool - Motley Fool - Wed Mar 18, 1:46PM CDT
All 31 of the nation's largest banks passed the first round of stress testing by the Federal Reserve, some with flying colors and others by the skin of their teeth. Second round results, announced this week, brought a few surprises. The Fool's...
SAN: 7.28 (+0.41), GS: 193.13 (+3.16), JPM: 61.75 (+0.55), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), MS: 36.50 (+0.39)
4 Energetic Global Dividend Dogs Flash 85% To 134% March Upsides
Fredrik Arnold - at Seeking Alpha - Wed Mar 18, 8:58AM CDT
SID: 1.78 (+0.11), TGA: 3.35 (+0.20), SAN: 7.28 (+0.41), E: 34.78 (+1.59), BAK: 7.40 (+0.22), CPL: 12.09 (+0.87), CIG: 3.92 (+0.30), TOT: 50.65 (+1.87), EC: 15.12 (+0.70), SBS: 5.85 (+0.45), ELP: 10.76 (+0.72), RIO: 43.58 (+1.50), VIV: 15.35 (-0.07), STO: 17.72 (+0.62)
Nasacort® Allergy 24HR Partners with The Book of Awesome Author and Renowned Smell Expert to Celebrate the Happy Smells of Spring
PR Newswire - Wed Mar 18, 7:45AM CDT
Nasacort® Allergy 24HR is teaming up with Neil Pasricha, an allergy sufferer and bestselling author of The Book of Awesome, as well as Dr. Charles J. Wysocki, a renowned expert on the science of smell, to educate Americans about the importance of smell and encourage them to celebrate the "awesome" scents of spring that often make us happy. Nasacort Allergy 24HR is scent and alcohol free and is available over-the-counter (OTC) at full prescription strength to help relieve nasal allergy symptoms like congestion, so even the worst allergy sufferer can enjoy the Happy Smells of spring.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
See How These Stocks Chosen 3 Years Ago Are Performing Today
Jae Jun - Seeking Alpha - Tue Mar 17, 2:39PM CDT
Got a nice surprise the other day. While rummaging through my documents and investing folders, I came across a simple test I ran in 2012 and 2013. It was a basic experiment where I asked old school value readers to submit and vote for 10 stocks to be...
VRX: 204.26 (+2.17), AEY: 2.34 (+0.01), BAC: 15.84 (+0.23), GLW: 23.39 (+0.26), WDC: 100.44 (+1.14), ORCL: 44.41 (+0.25), NOV: 49.66 (+1.77), SAN: 7.28 (+0.41), DLB: 39.25 (-0.03), GS: 193.13 (+3.16), GRVY: 0.49 (unch), AIG: 55.94 (+0.29), CAT: 81.19 (+1.10), CVX: 107.03 (+2.28), MSFT: 42.88 (+0.60), AAPL: 125.90 (-1.60)
GE Sells Aussie & Kiwi Finance Units to Trim Credit Risks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 2:49PM CDT
General Electric Company (GE) recently divested its financial services units in Australia and New Zealand for an enterprise value of A$8.2 billion ($6.3 billion).
SAN: 7.28 (+0.41), GE: 25.40 (+0.07), DB: 34.15 (+1.23), SYF: 32.25 (-0.12), KKR: 23.12 (+0.31)
As Volatility Creeps Back Up Towards Normal Levels, More Buying Opportunities Emerge
Claudio Brocado - at Seeking Alpha - Mon Mar 16, 2:49AM CDT
What I continue to call the most hated equity secular bull market of my career marches on, despite lingering geopolitical worries. There are no doubt many negatives and well known headwinds. Nevertheless, the positive forces pushing this bull market...
SAN: 7.28 (+0.41), QCOM: 70.04 (+0.21)
General Electric Sells Australia Unit For $6.3 Billion
at Investor's Business Daily - Sun Mar 15, 12:01PM CDT
General Electric (GE) will sell its consumer finance unit for Australia and New Zealand to Varde, KKR (KKR) and Deutsche Bank (DB) with an enterprise value of A$8.2 billion or $6.3 billion, the acquiring companies said Sunday. The local GE Capital...
SAN: 7.28 (+0.41), GE: 25.40 (+0.07), WMT: 83.24 (+1.72), DB: 34.15 (+1.23), SYF: 32.25 (-0.12), GPS: 43.16 (+0.39), KKR: 23.12 (+0.31)
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Bank Stock Roundup: Banks Rejoice on 2015 Capital Plan Approval amid Legal Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 2:45PM CDT
Over the last five trading days, optimism rose among investors as the Federal Reserve approved most of the banks' 2015 Capital Plan after clearance of the stress tests last week. This year, 28 financial institutions out of 31 in the Comprehensive Capital Analysis and Review (CCAR) got the Fed's approval.
SAN: 7.28 (+0.41), COF: 81.13 (+0.51), JPM: 61.75 (+0.55), USB: 44.86 (+0.42), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), WFC: 56.01 (+0.50), PNC: 95.97 (+1.10)
Stock Market News for March 13, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 9:10AM CDT
Benchmarks snapped two-day losses to end in the green on Thursday as mixed economic data reduced fears about sooner-than-expected rate hike
SAN: 7.28 (+0.41), GS: 193.13 (+3.16), MPC: 102.26 (+2.20), CHK: 13.61 (+0.11), C: 52.98 (+0.60), EOG: 90.68 (+1.15), DB: 34.15 (+1.23), WFC: 56.01 (+0.50), INTC: 31.31 (+0.57), KKD: 20.41 (-0.11), CVX: 107.03 (+2.28), MS: 36.50 (+0.39)
Santander Launches The I LOVE MY BANK(SM) Initiative
PR Newswire - Thu Mar 12, 11:33AM CDT
Santander Bank, N.A., announced today the launch of its I LOVE MY BANK initiative. The innovative colleague engagement and customer service program is part of the Bank's broader 2015 effort to strengthen its connection to its customers and colleagues - its two most important constituencies - through investing resources into enhancing those relationships.
SAN: 7.28 (+0.41)
Should Bank of America’s Stress Test Results Worry Shareholders?
Matthew Frankel, The Motley Fool - Motley Fool - Thu Mar 12, 11:04AM CDT
On Wednesday, the Federal Reserve announced the results of the second round of stress tests, and 29 of the 31 banks who were tested received approval for the capital plans they submitted. However, in arguably the biggest surprise of the stress tests,...
SAN: 7.28 (+0.41), DB: 34.15 (+1.23), BAC: 15.84 (+0.23)
Fed Approves Most Capital Plans: Banks on Path to Recovery? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 10:14AM CDT
Following the release of the Dodd-Frank Act supervisory stress test 2015 (DFAST 2015) results last week, the Federal Reserve approved the capital plans of 28 financial institutions out of 31 in the Comprehensive Capital Analysis and Review (CCAR).
FITB: 19.48 (+0.26), STT: 76.24 (+1.41), C: 52.98 (+0.60), DB: 34.15 (+1.23), BAC: 15.84 (+0.23), WFC: 56.01 (+0.50), MS: 36.50 (+0.39), SAN: 7.28 (+0.41), GS: 193.13 (+3.16), JPM: 61.75 (+0.55), COF: 81.13 (+0.51), USB: 44.86 (+0.42), PNC: 95.97 (+1.10), BK: 40.57 (+0.27)
